The University of Southampton
University of Southampton Institutional Repository

The use of weighted health-related Quality of Life scores in people with diabetic macular oedema at baseline in a randomized clinical trial

The use of weighted health-related Quality of Life scores in people with diabetic macular oedema at baseline in a randomized clinical trial
The use of weighted health-related Quality of Life scores in people with diabetic macular oedema at baseline in a randomized clinical trial

Aims: to examine the relationship between visual acuity in each eye and Quality of Life (QoL) outcomes in people with diabetic macular oedema.


Methods: cross sectional retrospective analysis of data collected at baseline in 289 people entered into a randomized clinical trial with diabetic macular oedema which investigated the safety and efficacy of a vascular endothelial growth factor inhibitor, pegaptanib sodium. At the baseline visit, visual acuity was measured through refraction and using retro-illuminated modified Early Treatment Diabetic Retinopathy Study Log MAR charts, and patient health-related QoL was determined using the European Quality of Life EQ–5D–3L and the Visual Functioning Questionnaire–25 (NEI–VFQ25). A regression analysis with QoL score from each vision-related domain as the dependent variable was fitted using linear and quadratic terms of the better and worse eye, age, gender, adjusted for number of concurrent conditions, ethnicity and level of diabetes control.


Results: for all vision-related QoL domains from NEI–VFQ25 and EQ–5D–3L except ocular pain, both visual acuity in the better-seeing and the worse-seeing eye gave a significant increase in correlation coefficient over that obtained from clinical and demographic data. The NEI–VFQ25 correlation was most closely associated with a weighted visual acuity measure of 0.75 in the better and 0.25 in the worse eye or 0.60 in the better and 0.40 in the worse eye.


Conclusions: we recommend that a weighted visual acuity measure from both eyes is considered in future diabetic macular oedema trials.

0742-3071
97-101
Scanlon, P.H.
4e3d2310-c79e-42db-ae29-7a7d6b278aa3
Loftus, J.
07adcd4d-fcd4-4af7-bf28-fa275d9237e2
Starita, C.
cbbb474c-6ed9-4d1c-922d-0e3327804bbe
Stratton, I.M.
772f25b9-23c0-4240-a3f6-1e76b03b172f
Scanlon, P.H.
4e3d2310-c79e-42db-ae29-7a7d6b278aa3
Loftus, J.
07adcd4d-fcd4-4af7-bf28-fa275d9237e2
Starita, C.
cbbb474c-6ed9-4d1c-922d-0e3327804bbe
Stratton, I.M.
772f25b9-23c0-4240-a3f6-1e76b03b172f

Scanlon, P.H., Loftus, J., Starita, C. and Stratton, I.M. (2014) The use of weighted health-related Quality of Life scores in people with diabetic macular oedema at baseline in a randomized clinical trial. Diabetic Medicine, 32 (1), 97-101. (doi:10.1111/dme.12593).

Record type: Article

Abstract

Aims: to examine the relationship between visual acuity in each eye and Quality of Life (QoL) outcomes in people with diabetic macular oedema.


Methods: cross sectional retrospective analysis of data collected at baseline in 289 people entered into a randomized clinical trial with diabetic macular oedema which investigated the safety and efficacy of a vascular endothelial growth factor inhibitor, pegaptanib sodium. At the baseline visit, visual acuity was measured through refraction and using retro-illuminated modified Early Treatment Diabetic Retinopathy Study Log MAR charts, and patient health-related QoL was determined using the European Quality of Life EQ–5D–3L and the Visual Functioning Questionnaire–25 (NEI–VFQ25). A regression analysis with QoL score from each vision-related domain as the dependent variable was fitted using linear and quadratic terms of the better and worse eye, age, gender, adjusted for number of concurrent conditions, ethnicity and level of diabetes control.


Results: for all vision-related QoL domains from NEI–VFQ25 and EQ–5D–3L except ocular pain, both visual acuity in the better-seeing and the worse-seeing eye gave a significant increase in correlation coefficient over that obtained from clinical and demographic data. The NEI–VFQ25 correlation was most closely associated with a weighted visual acuity measure of 0.75 in the better and 0.25 in the worse eye or 0.60 in the better and 0.40 in the worse eye.


Conclusions: we recommend that a weighted visual acuity measure from both eyes is considered in future diabetic macular oedema trials.

Text
Diabetic Medicine - 2014 - Scanlon - The use of weighted health‐related Quality of Life scores in people with diabetic - Version of Record
Download (66kB)

More information

Accepted/In Press date: 11 September 2014
e-pub ahead of print date: 23 September 2014
Published date: 13 October 2014

Identifiers

Local EPrints ID: 487144
URI: http://eprints.soton.ac.uk/id/eprint/487144
ISSN: 0742-3071
PURE UUID: 2d853d7b-1974-4d83-9eff-5a888bad1c87
ORCID for I.M. Stratton: ORCID iD orcid.org/0000-0003-1172-7865

Catalogue record

Date deposited: 14 Feb 2024 17:42
Last modified: 18 Mar 2024 04:01

Export record

Altmetrics

Contributors

Author: P.H. Scanlon
Author: J. Loftus
Author: C. Starita
Author: I.M. Stratton ORCID iD

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×